|Bid||80.71 x 800|
|Ask||80.74 x 900|
|Day's Range||80.57 - 81.19|
|52 Week Range||59.39 - 89.72|
|Beta (3Y Monthly)||1.29|
|PE Ratio (TTM)||21.72|
|Forward Dividend & Yield||2.28 (2.82%)|
|1y Target Est||N/A|
SpaceX successfully launched and landed its Falcon 9 rocket on the California coast today. Andrew Chanin, ProcureAm Co-Founder & CEO, joins Seana Smith on 'The Ticker' to discuss how his company's ETF is giving investors access into the space race.
This week, we look at the relocation of USDA jobs to KC (and more), the future of Schlitterbahn (and more) and the passing of Garmin co-founder Gary Burrell (yes, you guessed it).
Garmin CEO Cliff Pemble reflects on Gary Burrell's shy nature, passion for creating products and his lasting influence on company culture after the co-founder and chairman emeritus died Wednesday at age 81.
Gary Burrell, Garmin Ltd. co-founder and chairman emeritus, died at age 81 on Wednesday. The billionaire retired in 2002 and continued as Garmin’s co-chairman until 2004, when he was named as chairman emeritus. Burrell and Min Kao co-founded the Olathe-based company (Nasdaq: GRMN) in 1989.
The fast-growing $384 billion space industry is generating investor interest, and one recently launched exchange-traded fund, Procure Space ETF (UFO), is giving Wall Street a way to play the sector.
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
This post was done in partnership with Wirecutter. The street price of this model has fallen since the release of the Gen 2 version, but the original Gen 1 is still recommended. It makes for a nice addition to an existing Sonos setup or a good starter speaker if you like the color.
Moody's Investors Service ("Moody's") has today downgraded Nanna Midco II AS' (Navico or the company) corporate family rating (CFR) to B3 from B2 and probability of default rating (PDR) to B3-PD from B2-PD. Moody's has also downgraded to B3 from B2 the instrument rating of the USD260 million senior secured term loan due 2024 (the term loan) and to Ba3 from Ba2 the instrument rating of the USD25 million super senior revolving credit facility (RCF) maturing in 2023, both issued by Navico Inc., a subsidiary of Nanna Midco II AS.
There's no question that dedicated GPS units are on the decline in an era whenyour smartphone is often good enough for navigation, if not better
Garmin will provide wearables for Saint Luke's cancer patients for a study that will aim to create predictive insights to improve patient lifespans.
Garmin (GRMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
The lawsuit alleges the company's marketing of personal navigation devices is misleading because the claims on the box don't match the wording of the warranty.
With GPS now a basic cell phone feature , and more vehicles rolling off the production lines with built-in satnav systems, the role of standalone satellite-navigation devices is diminishing. Why have an extra bit of kit in your car that needs additional maintenance? But Garmin thinks there's still a place for them, particularly in the world of off-roading and overlanding.
Improvement in profitability and outperformance against the industry can be important characteristics in a stock for...
Fitbit (NASDAQ: FIT) reported stronger than expected first quarter results on May 1. In addition to meaningfully beating top line and bottom line expectations, the results included multiple, other items that are tremendously positive for Fitbit stock.Source: Fitbit The company's revenue rose 10% year-over-year, its tracker revenue rose YoY for the first time in three years, its smartwatch revenue soared 117% YoY, and the revenue it obtains from companies and insurers jumped 70% YoY.Furthermore, FIT did not raise its 2019 guidance, but said it was not doing so only because it chose to be "prudent," a code word for conservative.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Strong Buy Stocks That Tick All the Boxes A Closer Look at FITStill, Fitbit stock fell meaningfully, as investors chose to focus on the few negative aspects of the company's results, including lower average selling prices and conservative Q2 guidance.I believe that these investors are making the classic mistake of focusing on the trees instead of the forest. That's because I think that FIT has a tremendous monetization opportunity that will enable Fitbit stock to at least double over the next year or two. Fitbit's strategy for monetizing its users on a massive level is becoming clear.FIT CEO James Park reported that a large study of diabetes prevention methods found that people who used Fitbit devices, "were more active and lost more weight during the program than those who did not and were more likely to be engaged in the platform a year later."Additionally, subjects who used Fitbit devices averaged an hour more activity per week for much of the program than those who did not, he stated.Clearly, people who use step-tracking devices are more active and, consequently, less like to have diabetes, heart disease and some forms of cancer than those who do not use such devices.As I've written previously, insurers and employers have tremendous incentive to keep their employees and clients healthier.As a result, they will likely be willing to pay meaningful amounts of money to do so. Opportunities Abound for FitbitFitbit is already taking advantage of this opportunity on multiple fronts. Many Medicare Advantage programs, spread around 27 states, are covering Fitbit devices, Park reported. Furthermore, three national health plans are currently using Fitbit Care as their means for diabetes management. "There's a lot of interest (among insurers) in our Fitbit Care product," Park said. With Fitbit Care, the company analyzes patients' data it obtains from its own devices as well as other devices. and uses that data to offer patients ways of improving their health. In the second half of this year, FIT plans to launch a premium offering for individuals based on Fitbit Care. I believe that, over time, Fitbit Care will be adopted by many employers, health insurers, and individuals. As everyone knows, obesity is a major problem in the U.S. and leads to tremendous health problems. Under the principle that "what gets measured gets managed," step-tracking devices definitely help people become more active. Employers and health insurers have a financial interest in keeping their employees and clients healthy. And individuals, of course, have many reasons to want to be healthier and avoid obesity, and Americans already spend a great deal of time and money seeking to accomplish those goals. Therefore, I believe that there's a tremendous addressable market for Fitbit's devices, encompassing both enterprises and individuals. If FIT can obtain a sizable piece of that market, FIT's results and FIT stock will definitely rise tremendously over the long-term. Fitbit Stock and the Monetization WarFitbit is in a "sweet spot" that will allow it to become the leader of this huge addressable market. The smartwatches sold by Apple (NASDAQ: AAPL) and Garmin (NASDAQ:GRMN) are too expensive for most enterprises and many people who want to use step trackers to improve their health. At the same time, many enterprises and people will not be ready to trust Chinese companies who sell cheaper step trackers, but don't have well-respected brand names, with the important task of helping themselves or their clients/employees improve their health. That leaves Fitbit and Samsung as the remaining options, and FIT's devices already meaningfully outsell those of Samsung, giving FIT an important advantage over its Korean competitor. I was disappointed that FIT did not make any new announcements regarding its devices' ability to diagnose diseases or take measurements that are crucial for individuals' health, such as blood oxygen levels or sleep apnea. In the past, I have said that Fitbit must make positive strides in those areas for FIT stock to rally. Still, the company noted that it was continuing to work with the FDA to "test and develop" those types of solutions, and I recognize that it takes a long time to get the agency to approve devices. More importantly, I'm now convinced that, over the next year or two, monetizing Fitbit Care will prove to be a tremendous, positive catalyst for FIT's results and FIT stock., enabling Fitbit stock to at least double during that time As of this writing, the author owned shares of FIT stock. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Strong Buy Stocks That Tick All the Boxes * 7 Stocks to Buy From the T. Rowe Price Health Sciences Fund * 5 Tech ETFs to Plug In to Big Profits Compare Brokers The post Why Fitbit Stock Is Poised to at Least Double by 2021 appeared first on InvestorPlace.
Garmin Ltd NASDAQ/NGS:GRMNView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for GRMN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting GRMN. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $1.78 billion over the last one-month into ETFs that hold GRMN are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Industrials sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.